NCT04306081 - Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

December 30, 2020

Study Completion Date

March 30, 2021

Conditions

Peripheral Arterial Disease

Interventions

DRUG

Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.

The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen

OTHER

Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.

The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen

Trial Locations (1)

90033

RECRUITING

University of Southern California, Los Angeles